Science Explorer Back to mapMap
Discussion
Company · Morristown · United States

Newron Pharmaceuticals (United States)

newron.com/enROR OpenAlex
Research works
8
▲ 381% vs 2018-21
Citations
69
8.4 per fractional work
Top-10% rate
2.3%
all institutions 10.0%
Open access
54%
world 40%
International
64%
world 18%
Newron Pharmaceuticals (United States)

Not ranked overall: Newron Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Newron Pharmaceuticals (United States) work in?

In all years, 46% of research at Newron Pharmaceuticals (United States) is in Health Sciences, 20% in Life Sciences. Its largest fields are Medicine (44%), Engineering (18%), Biochemistry, Genetics and Molecular Biology (14%). It does 1.4× the world's share of Health Sciences.

Health Sciences: 4 fractional works · 46.5% of its workMedicine: 4 fractional works · 44.4% of its workPsychiatry and Mental health: 2 fractional works · 27.7% of its workPharmacology: 1 fractional works · 6.8% of its workNeurology: 0 fractional works · 2.4% of its workPhysiology: 0 fractional works · 2.2% of its workSurgery: 0 fractional works · 1.7% of its workComplementary and alternative medicine: 0 fractional works · 1.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.3% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 1.0% of its workNursing: 0 fractional works · 2.1% of its workNutrition and Dietetics: 0 fractional works · 2.1% of its workLife Sciences: 2 fractional works · 19.5% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 13.6% of its workGenetics: 1 fractional works · 9.5% of its workMolecular Biology: 0 fractional works · 3.8% of its workBiochemistry: 0 fractional works · 0.4% of its workNeuroscience: 0 fractional works · 5.1% of its workCellular and Molecular Neuroscience: 0 fractional works · 2.7% of its workCognitive Neuroscience: 0 fractional works · 1.3% of its workNeurology: 0 fractional works · 1.1% of its workImmunology and Microbiology: 0 fractional works · 0.8% of its workImmunology: 0 fractional works · 0.8% of its workPhysical Sciences: 2 fractional works · 18.2% of its workEngineering: 2 fractional works · 18.2% of its workIndustrial and Manufacturing Engineering: 1 fractional works · 12.1% of its workMechanical Engineering: 0 fractional works · 3.0% of its workOcean Engineering: 0 fractional works · 3.0% of its workSocial Sciences: 1 fractional works · 15.8% of its workBusiness, Management and Accounting: 1 fractional works · 12.1% of its workAccounting: 1 fractional works · 12.1% of its workPsychology: 0 fractional works · 2.7% of its workClinical Psychology: 0 fractional works · 1.3% of its workExperimental and Cognitive Psychology: 0 fractional works · 1.3% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.6% of its workEconomics and Econometrics: 0 fractional works · 0.6% of its workDecision Sciences: 0 fractional works · 0.4% of its workStatistics, Probability and Uncertainty: 0 fractional works · 0.4% of its workALL ITS WORKNewronPharmaceuticals…8fractional works, all years
Life Sciences20%Physical Sciences18%Health Sciences46%Social Sciences16%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 10 fields, with their numbers
    1. Medicine444.4%
    2. Nursing02.1%
    1. Biochemistry, Genetics and Molecular Biology113.6%
    2. Neuroscience05.1%
    3. Immunology and Microbiology00.8%
    1. Engineering218.2%
    1. Business, Management and Accounting112.1%
    2. Psychology02.7%
    3. Economics, Econometrics and Finance00.6%
    4. Decision Sciences00.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Newron Pharmaceuticals (United States)?

The most cited paper from Newron Pharmaceuticals (United States) is "Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia" (Martin K.-H. Schäfer, Wilhelm Schwaeble, Claes Post et al., 2000), with 177 citations. Next come "Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study" (71) and "Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects" (55).

Most cited papers
#PaperReleasedCitations
1 Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia Martin K.-H. Schäfer, Wilhelm Schwaeble, Claes Post et al. · The Journal of Immunology Open access May 2000 177
2 Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study Eliot A. Brinton, Christie Mitchell Ballantyne, Harold Edward Bays et al. · Cardiovascular Diabetology Open access 2013 71
3 Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects Rene A. Braeckman, William G. Stirtan, Paresh N. Soni · Clinical Pharmacology in Drug Development Open access 11 Oct 2013 55
4 Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies Antonio Y. Hardan, Robert L. Hendren, Michael G. Aman et al. · Autism Open access 26 Apr 2019 51
5 Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study Andrew P. Ambrosy, Jingrong Yang, Sue Hee Sung et al. · Journal of the American Heart Association Open access 8 Oct 2021 32
All 25 most cited papers, with filters and sorting

Which research topics does Newron Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Schizophrenia research and treatment, Treatment of Major Depression, Bipolar Disorder and Treatment and BRCA gene mutations in cancer.

Schizophrenia research a…2Schizophrenia research and treatment: 2 fractional worksTreatment of Major Depression: 1 fractional worksBipolar Disorder and Tre…0Bipolar Disorder and Treatment: 0 fractional worksBRCA gene mutations in c…0BRCA gene mutations in cancer: 0 fractional worksNeuroscience and Neuropharmacology Research: 0 fractional worksGenomics and Rare Diseases: 0 fractional worksMedicinal Plants and Neuroprotection: 0 fractional worksDiet and metabolism studies: 0 fractional worksParkinson's Disease Mechanisms and Treatments: 0 fractional worksNeurological disorders and treatments: 0 fractional works
Psychiatry and Mental healthPharmacologyGeneticsCellular and Molecular Neuroscience3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Schizophrenia research and treatment Psychiatry and Mental health 2 works
  2. 2 Treatment of Major Depression Pharmacology 1 works
  3. 3 Bipolar Disorder and Treatment Psychiatry and Mental health 0 works
  4. 4 BRCA gene mutations in cancer Genetics 0 works
  5. 5 Neuroscience and Neuropharmacology Research Cellular and Molecular Neuroscience 0 works
  6. 6 Genomics and Rare Diseases Genetics 0 works
  7. 7 Medicinal Plants and Neuroprotection Complementary and alternative medicine 0 works
  8. 8 Diet and metabolism studies Physiology 0 works
  9. 9 Parkinson's Disease Mechanisms and Treatments Neurology 0 works
  10. 10 Neurological disorders and treatments Neurology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available54.5%not open45.5%

World: 40% of research is openly available.

with international co-authors64.4%domestic only35.6%

World: 18% is written across borders.

How has Newron Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 381% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Newron Pharmaceuticals (United States) as a percentage of every work published that year, 0.0000045% in 2024.

still counting0.00010%0.00020%0.00030%Newron Pharmaceuticals (United States)0.000049% in 20251990200020102020

Fractional works of Newron Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Morristown

All research institutions in Morristown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Newron Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.